Anita Szőke

Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

Talha Munir, Jennifer R. Brown, Susan O’Brien et al. · American Journal of Hematology · 2019 · 451 citations · Full text

Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis

John Mascarenhas, Ronald Hoffman, Moshe Talpaz et al. · JAMA Oncology · 2018 · 358 citations · Full text

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial

Ruben A. Mesa, Alessandro M. Vannucchi, Adam J. Mead et al. · The Lancet Haematology · 2017 · 300 citations · Full text

Hematological Malignancy, Oncology, Pacritinib Versus +9

Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia 

Paul M. Barr, Carolyn Owen, Tadeusz Robak et al. · Blood Advances · 2022 · 246 citations · Full text

Ibrutinib Vs 9, Chronic Lymphocytic Leukemia, Immunology +16

Stroke in essential thrombocythemia

Éva Pósfai, Imelda Marton, Anita Szőke et al. · Journal of the Neurological Sciences · 2013 · 43 citations

Thrombosis, Venous Thrombosis, Ischemic Stroke +11